At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract
In Brief
A Phase 2 clinical trial evaluating single arm dose dense MVAC for Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tracts. Completed, enrolled 54 participants across 2 sites.
Detailed Summary
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of cure. The M V chemotherapy is usually given every 14 days with the AC given along each 28 days. This study looks at giving the same drugs at the same doses closer together, all drugs every 14 days, with the support of growth factor medication to promote growth of the white blood cells and platelets and allow chemotherapy to be finished sooner and surgery to be done sooner.
Study Details
Timeline
Interventions
standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.